

## Sacituzumab govitecan (solution)

Cat. No.:	HY-132254A	
CAS No.:	1491917-83-9	
Target:	Antibody-Drug Conjugates (ADCs)	
Pathway:	Antibody-drug Conjugate/ADC Related	Sacituzumab govitecan (solution)
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.	

### BIOLOGICAL ACTIVITY

#### Description

Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38. Sacituzumab govitecan shows anticancer activity<sup>[1]</sup>.

### CUSTOMER VALIDATION

- J Control Release. 2024 Feb 13:367:779-790.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

### REFERENCES

[1]. Cardillo TM, et al. Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers. *Bioconjug Chem.* 2015 May 20;26(5):919-31.

[2]. Goldenberg DM, Cardillo TM, Govindan SV, Rossi EA, Sharkey RM. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) [published correction appears in *Oncotarget.* 2020 Mar 10;11(10):942]. *Oncotarget.* 2015;6(26):22496-22512.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA